Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 >= 50% and without actionable genomic alterations-MedSci.cn

Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 >= 50% and without actionable genomic alterations

Levy, BP; Reck, M; Yang, JCH; Cappuzzo, F; Rawat, S; Xie, JD; Basak, P; Felip, E

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务